FDA deepens Vertex's Casgevy label to include patients as young as 2 on July 06, 2026 age 2 Anemia, Sickle Cell Approved Casgevy Clustered Regularly Interspaced Short Palindromic Repeats gene therapy Pediatric brand name United States Food and Drug Administration +